Valuation: Genmab A/S

Market Cap 115B 17.58B 15.32B 14.3B 13.16B 24.67B 1,682B 25.29B 169B 66.29B 835B 66.02B 64.59B 2,871B P/E 2026 *
24.4x
P/E 2027 * 16.9x
Enterprise Value 134B 20.56B 17.91B 16.72B 15.39B 28.84B 1,967B 29.57B 198B 77.52B 977B 77.2B 75.53B 3,357B EV / Sales 2026 *
4.74x
EV / Sales 2027 * 3.81x
Free-Float
95.41%
Yield 2026 *
-
Yield 2027 * -
1 day-1.66%
1 week+0.55%
Current month+3.82%
1 month+9.19%
3 months+6.46%
6 months-13.39%
Current year-7.40%
1 week 28.33
Extreme 28.33
29.38
1 month 27.33
Extreme 27.33
29.8
Current year 23.62
Extreme 23.62
35.43
1 year 21
Extreme 20.995
35.43
3 years 17.24
Extreme 17.235
41.58
5 years 17.24
Extreme 17.235
49.07
10 years 12.1
Extreme 12.1
49.07
Manager TitleAgeSince
Chief Executive Officer 65 01/06/2010
Director of Finance/CFO 48 01/03/2020
Chief Tech/Sci/R&D Officer - 16/08/2024
Director TitleAgeSince
Director/Board Member 75 01/11/2003
Director/Board Member 58 01/01/2015
Director/Board Member 75 01/01/2015
Change 5-day change 1-year change 3-year change Capi.($)
-1.66%+0.55% - - 17.86B
+0.47%+2.03%+51.54%+70.84% 55.01B
+2.83%+0.04%+38.07%+82.59% 54.24B
+0.54%+0.67%-17.59%-13.47% 23.38B
-0.97%-5.06%+1.35%+383.00% 22.57B
+2.07%+1.44%+23.06%-9.05% 20.19B
-2.14%-2.72%+30.26%+536.72% 15.5B
-3.14%-8.09%+160.68%+292.18% 14.2B
-2.09%-1.41%+24.65%+178.74% 14.2B
+1.50%+0.02%+85.91%+166.11% 12.42B
Average -0.26%-0.57%+44.21%+187.52% 25.75B
Weighted average by Cap. +0.37%-0.28%+39.50%+144.98%

Financials

2026 *2027 *
Net sales 28.25B 4.33B 3.78B 3.52B 3.24B 6.08B 414B 6.23B 41.73B 16.34B 206B 16.27B 15.92B 708B 33.18B 5.09B 4.43B 4.14B 3.81B 7.14B 487B 7.32B 49.02B 19.19B 242B 19.11B 18.7B 831B
Net income 4.82B 739M 644M 601M 553M 1.04B 70.66B 1.06B 7.11B 2.78B 35.09B 2.77B 2.71B 121B 7.05B 1.08B 943M 880M 810M 1.52B 104B 1.56B 10.42B 4.08B 51.41B 4.06B 3.98B 177B
Net Debt 19.4B 2.98B 2.59B 2.42B 2.23B 4.18B 285B 4.28B 28.66B 11.22B 141B 11.18B 10.93B 486B 11.82B 1.81B 1.58B 1.47B 1.36B 2.54B 173B 2.61B 17.46B 6.84B 86.14B 6.81B 6.66B 296B
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,088
Date Price Change Volume
29/07/26 US$28.52 -1.66% 1,160,555
28/07/26 US$29.00 +0.69% 2,212,644
27/07/26 US$28.80 -0.24% 1,526,784
24/07/26 US$28.87 -1.03% 1,676,219
23/07/26 US$29.17 +1.11% 1,135,422
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
1,867.00DKK
Average target price
2,392.08DKK
Spread / Average Target
+28.12%

Quarterly revenue - Rate of surprise